Bayer Gets in China Its First Global Approval for Stroke Prevention Drug
The decision hands Bayer the first ever approval for a Factor XIa inhibitor, which aim to slow the activity of
Health
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
The Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to
Sharpen memory and fight brain fog with simple 60-second trick from a neurologist
NEWYou can now listen to Fox News articles! Brain games, crosswords and math puzzles are often promoted as ways to
Selena Gomez’s vaping admission highlights hidden health risks doctors say millions face daily
NEWYou can now listen to Fox News articles! When Selena Gomez revealed to her millions of followers that heavy nicotine
Catholic alcohol consumption drops to record low as Americans rethink moderate drinking habits
NEWYou can now listen to Fox News articles! A historic shift in American drinking habits shows Catholic alcohol consumption reaching
Jalen Hurts puts spotlight on blood thinners: 5 mistakes that could put patients at risk
NEWYou can now listen to Fox News articles! Philadelphia Eagles quarterback Jalen Hurts’ diagnosis of blood clots in both lungs
Christina Applegate’s MS misdiagnosis after 5 years of treatment exposes alarming medical reality
NEWYou can now listen to Fox News articles! Christina Applegate’s recent revelation that she was misdiagnosed with multiple sclerosis is
Heard on the Street: Moderna’s cancer vaccine passed its first big test this past week. The bigger problem is that its stock is priced as if it has already passed them all.
Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes. Source link
To the scientific world, Moderna’s cancer vaccine’s results proved that a highly personalized, immune-targeting medication can work. To investors, it didn’t work well enough.
The company’s stock dropped after details of a study raised questions about how widely the treatment would be used. Source